Zamosc

• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised
  2022-500535-36-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye … Pending
  2024-513740-28-00 5 Respiratory Syncytial Virus and Human Metapneumovirus
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• A Study of Enpatoran in Cutaneous Manifestations of Lupus With or Without Systemic Disease Pending
  2025-523871-44-00 5 Cutaneous Manifestations of Lupus Erythematosus With or Without System
• J6Z-MC-IIBD - A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Stud … Pending
  2025-524112-11-00 4 J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD01 - Crohn
• A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3) Recruiting
  2025-524404-29-00 4 2026-06-24 Ulcerative Colitis, Active Moderate
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with … Recruiting
  2023-510369-92-00 4 2025-01-28 Mixed Dyslipidemia
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Recruiting
  2025-523486-17-00 5 2026-06-16 Obesity
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting
  2025-522338-30-00 4 2026-03-31 Ulcerative Colitis
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting
  2024-519712-13-00 5 2025-12-08 Hypertriglyceridemia (HTG)
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co … Recruiting
  2025-520690-39-00 4 2025-11-04 Moderately to Severely Active Ulcerative Colitis (UC)

Showing 1–24 of 84 trials